![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 33,133 | 08:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/4/2020 16:35 | RNS guaranteed tomorrow, we had already so many so, another one tomorrow is 100% sure | ![]() the patient investor | |
06/4/2020 16:33 | Nobby, I think the large pharma's know the results will be positive and will want to tie something up asap. It has been speculated that Richard has been in meetings for the last fortnight with large pharmas and although still in trial I believe something will be tied up before the final data comes through. I know this is not the done way, but again, this is all unprecedented. | ![]() likya123 | |
06/4/2020 16:32 | I can't see anything more company transforming than the Covid 19 trial result... | ![]() nobbygnome | |
06/4/2020 16:30 | Which will contain what? Not ruling it out but... | ![]() nobbygnome | |
06/4/2020 16:28 | I believe there will be a company transforming one well before that time period....time will tell. | ![]() likya123 | |
06/4/2020 16:27 | >> likya I don't know why you are so worried about an RNS in the very near future. The only one which matters will be in about 7 or 8 weeks time. That is what you should focus on... | ![]() nobbygnome | |
06/4/2020 16:24 | could be a placing block sell - so making 13p profit from the 35p placing price - but at least it's now been completed | ![]() euclid5 | |
06/4/2020 16:18 | No ramping but.... Apart from I genuinely believe this could be share of the century we have just been taken down to fill some very large buys and zipping up into close with what looks like a really strong finish...got a feeling we may see a 7am RNS tomorrow. An extended auction adding a penny or two and I'll be convinced. | ![]() likya123 | |
06/4/2020 16:02 | >> timbo Yes gamma is completely different from the other forms and is largely a T cell cytokine so not really an anti viral molecule. I must admit I didn't know there was a lambda which is an embarrassing hole in my knowledge. I will have to go away and read about it! | ![]() nobbygnome | |
06/4/2020 15:53 | Also noteworthy that Synairgen have filed some IP in the area of Lamda interferon in the past (in addition to the main beta interferon patents): | ![]() timbo003 | |
06/4/2020 15:48 | Re post 2595 Indeed Nobby there is a gamma interferon and a lamda interferon (how many greek letters are there?) This is definitely not my area of expertise, but following a quick persusal it seems to me that gamma interferon may exacerbate the problems of viral infection under certain circumstances, whereas lamda may help Gamma: Lamda: | ![]() timbo003 | |
06/4/2020 15:31 | Last of placing | ![]() bobaxe1 | |
06/4/2020 15:25 | Doubt it. A worked sell order I presume is a safer assumption based on price weakness. | ![]() insideryou | |
06/4/2020 15:22 | Inovio, a leading us vaccine co that has always specialised in rare viruses like SARS and mers has just gone into P1 with a vaccine. Timeline is end 2020 for 1m vaccines as a context. | ![]() slicethepie | |
06/4/2020 15:21 | Looks like a buy to me. Apr 6 2020, 15:09 48.837 220,000 48.00 49.00 Buy £107,441.4 | ![]() 2nell | |
06/4/2020 15:21 | Either way it's done and out the way | ![]() tialouise | |
06/4/2020 15:18 | Are we sure that's a buy. | ![]() royalalbert | |
06/4/2020 15:14 | £107k buy and a few other hefty buys....big confidence! the price was taken down to fill them. | ![]() likya123 | |
06/4/2020 15:09 | Interesting article on the route to market in the US It looks like Gilead's antiviral Remdesivir may be first to be in use from the summer and could provide a good roadmap for SNG to follow. As well as being a life saver it is estimated that a successful drug could add a trillion dollars to get the US economy moving again. | ![]() pdt | |
06/4/2020 14:49 | Finally added a few more with the price dipping below 50p. Still intend to sell some off before the results if things start heating up. | ![]() adman50 | |
06/4/2020 14:45 | Also from lse board.. To add to the credibility to the above article. The Dr in question. | ![]() likya123 | |
06/4/2020 13:45 | They know it works, just confirming in pilot trials for the rubber stamp.... From lse board.. Very interesting. Particularly as the Chinese seem to have founded interferon B as one of the two treatments to position. Great post. 'China’s government has issued a directive with guidance to that end, recommending doctors should try two different treatments.' 'One is the combination of drugs used to treat HIV/AIDS. The drugmaker, AbbVie, was quick to promote the concept of a clinical trial for coronavirus last week.' 'The Chinese directive recommended two doses of inhaled interferon per day for coronavirus patients.' 'In 2003, Fish was the interferon expert on a team of doctors who tried the treatment on SARS patients in Toronto. Though they didn’t conduct a formal study, they found the patients given interferon got better quicker than those who weren’t.' 'Though China’s directive is to try interferon, it’s not part of the global response to the virus.' | ![]() likya123 | |
06/4/2020 13:21 | But there is also a gamma 😜😂.. | ![]() nobbygnome | |
06/4/2020 13:04 | Likya Well, it is called 'Beta' Interferon for a reason. :o) | ![]() jev1 | |
06/4/2020 12:58 | It was listed in the appendix of the Recovery study protocol that beta interferon should be better than alpha. | ![]() nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions